**NeOnc Technologies Holdings, Inc. Reports Financial Results and Operational Progress in 10-K Filing**
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for intracranial malignancies, released its financial results and provided an update on its operational activities in its recent 10-K filing. The company, which was formed in 2008, is currently developing two lead products: NEO100 and NEO212. As of March 30, 2026, the company had 5 full-time employees.
The company reported a net loss of $62.15 million for the year ended December 31, 2025, compared to a net loss of $11.90 million for the previous year. Research and development expenses increased to $3.64 million from $3.05 million, primarily due to the expansion of clinical trial sites for NEO100, recruitment for NEO212, and the start of a clinical trial for a pediatric indication. General and administrative expenses also saw a significant increase, rising to $4.82 million from $1.68 million, driven by an investor awareness marketing campaign, increased employee headcount, and related compensation and benefits. The company generated revenue of $39,990 and $83,000 for the years ended December 31, 2025 and 2024, respectively, from fees for a "right to try" humanitarian program.
Operationally, NeOnc has made progress with its lead product candidates. A Phase IIa trial of intranasal NEO100 for patients with malignant skull-based meningioma was launched in July 2023. The company also completed the dose-escalation portion of its NEO212-01 Phase 1/2 clinical trial, establishing the recommended Phase 2 dose (RP2D) at 610 mg. The company plans to engage with the FDA to review safety, pharmacokinetics, and preliminary efficacy data, as well as the proposed Phase 2 study design. In 2025, NeOnc acquired an intellectual property portfolio comprising artificial intelligence–driven drug discovery tools, rapid magnetic 3D bioprinting technology, and quantum molecular modeling capabilities for $3.5 million.
Looking ahead, NeOnc aims to change the cancer therapeutic landscape by developing novel therapeutic approaches leveraging dual approaches of novel drug delivery methods in combination with novel drug candidates that potentially lead to better therapeutic results with low side effects. The company anticipates a potential readout for its Phase II studies with respect to NEO100 by the end of 2024. The company is also planning a clinical trial of intranasal NEO100 mixed with levodopa for patients with Parkinson’s disease. The company's auditor included an explanatory paragraph indicating that there was substantial doubt about the company’s ability to continue as a going concern.
About NEONC TECHNOLOGIES HOLDINGS, INC.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.